MedTrace Logo

DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer

NCT03657966 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2021-04-21

No results posted yet for this study

Summary

The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes in women with FIGO stage III and IV epithelial ovarian carcinoma who experienced relapse more than 6 months after complete remission of first line platinum-based chemotherapy (platinum sensitive ovarian cancer)

Conditions

  • Ovarian Cancer Recurrent

Interventions

BIOLOGICAL

DCVAC/OvCa

activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy

DRUG

Standard of Care Chemotherapy

either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa

Sponsors & Collaborators

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Harald Fricke, MD, PhD · SOTIO a.s.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-23
Primary Completion
2020-11-11
Completion
2021-02-25

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03657966 on ClinicalTrials.gov